Positron emitting 18F-2-deoxy-2-fluoro-D-glucose: potential hot new therapy.
Preclinical studies suggest that 18F-2-deoxy-2-fluoro-D-glucose (18F-FDG) kills breast cancer cells without significant marrow toxicity or parenchymal toxicity. Radiation dose calculations estimated from fluorodeoxyglucose positron emission tomography images in women with metastatic disease indicate that 18F-FDG should be a feasible and safe option in humans. Because the available radiotherapeutic agents, strontium 89 and samarium 153 provide palliation to a limited population of women with bony metastases, new radiopharmaceutical agents with broader applicability are needed. The development of 18F-FDG as the first positron-emitting radiotherapeutic has the potential to be an innovative treatment, not only in osteoblastic disease, but also in osteolytic disease and in soft tissue metastases.
Eastern Virginia Medical School, Department of Medicine, Division of Medical Oncology, Norfolk, Virginia, USA. mortimje@EVMS.edu
Joanne E
JE
Mortimer
Marie E
ME
Taylor
D000818:Animals; D001943:Breast Neoplasms / Q000000981:diagnostic imaging / Q000473:pathology / Q000532:radiotherapy*; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000627:therapeutic use*; D006801:Humans; D008325:Mammary Neoplasms, Experimental / Q000000981:diagnostic imaging / Q000473:pathology / Q000532:radiotherapy; D051379:Mice; D019275:Radiopharmaceuticals / Q000627:therapeutic use*; D014055:Tomography, Emission-Computed
D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18